This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Smith, H. J. Articles by Tisdale, M. J. Search for Related Content PubMed PubMed Citation Articles by Smith, H. J. Articles by Tisdale, M. J.

Effect of a Cancer Cachectic Factor on Protein Synthesis/Degradation in Murine C₂C₁₂ Myoblasts: Modulation by Eicosapentaenoic Acid¹

Pharmaceutical Sciences Institute, Aston University, Birmingham B4 7ET, United Kingdom

The effect of a proteolysis inducing factor (PIF) on protein synthesis and degradation and the modulation of this effect by the polyunsaturated fatty acid, eicosapentaenoic acid (EPA), have been examined using a surrogate model system, C₂C₁₂ myoblasts in vitro. After 90 min of incubation, PIF produced a significant inhibition of protein synthesis in a dose-dependent manner, with maximal inhibition at a concentration of 4 nM. The effect was attenuated both by treatment with a monoclonal antibody to PIF and by treatment with insulin at physiological concentrations (1 nM) and below (0.1 nM), but not by EPA (50 µM). The inhibitory effect on protein synthesis was transitory and was not seen after prolonged incubation with PIF. An increased rate of protein degradation was observed in C₂C₁₂ myoblasts after addition of PIF, which was also maximal at a concentration of PIF of 4 nM. Higher concentrations of PIF did not produce an increase in protein degradation. Unlike the effect on protein synthesis, the enhanced protein degradation was completely abolished by pretreatment with 50 µM EPA, suggesting that the two effects are mediated by different mechanisms. PIF produced an increased release of [³H]arachidonic acid from prelabeled myoblasts with a dose-response curve parallel to that of protein degradation and with a maximum at 4 nM PIF. Release of [³H] arachidonic acid was completely blocked in cells pretreated with 50 µM EPA, suggesting that the effect was related to protein degradation. The [³H]arachidonic acid was rapidly metabolized to prostaglandins E₂ and F₂ and to 5-, 12-, and 15-hydroxyeicosatetraenoic acids (HETEs). Production of all eicosanoids was attenuated in cells pretreated with EPA. Of all of the metabolites, only 15-HETE produced a significant increase in protein degradation in C₂C₁₂ myoblasts with a maximal effect at 30 nM and with a bell-shaped dose-response curve similar to that produced by PIF. These results suggest that PIF enhances protein degradation as a result of an increased production of 15-HETE.

This article has been cited by other articles:

				S. Al-Majid and H. Waters The Biological Mechanisms of Cancer-Related Skeletal Muscle Wasting: The Role of Progressive Resistance Exercise Biol Res Nurs, July 1, 2008; 10(1): 7 - 20. [Abstract] [PDF]

				K.-A. Kim, S.-O Ka, W. S. Moon, H.-K. Yi, Y.-H. Lee, K.-B. Kwon, J.-W. Park, and B.-H. Park Effect of dermcidin, an antimicrobial peptide, on body fat mobilization in normal mice J. Endocrinol., July 1, 2008; 198(1): 111 - 118. [Abstract] [Full Text] [PDF]

				H. L. Eley, S. T. Russell, J. H. Baxter, P. Mukerji, and M. J. Tisdale Signaling pathways initiated by beta-hydroxy-beta-methylbutyrate to attenuate the depression of protein synthesis in skeletal muscle in response to cachectic stimuli Am J Physiol Endocrinol Metab, October 1, 2007; 293(4): E923 - E931. [Abstract] [Full Text] [PDF]

				B. M. Wieland, G. D. Stewart, R. J.E. Skipworth, K. Sangster, K. C.H. Fearon, J. A. Ross, T. J. Reiman, J. Easaw, M. Mourtzakis, V. Kumar, et al. Is There a Human Homologue to the Murine Proteolysis-Inducing Factor? Clin. Cancer Res., September 1, 2007; 13(17): 4984 - 4992. [Abstract] [Full Text] [PDF]

				H. L. Eley and M. J. Tisdale Skeletal Muscle Atrophy, a Link between Depression of Protein Synthesis and Increase in Degradation J. Biol. Chem., March 9, 2007; 282(10): 7087 - 7097. [Abstract] [Full Text] [PDF]

				R. Siddiqui, D. Pandya, K. Harvey, and G. P. Zaloga Nutrition Modulation of Cachexia/Proteolysis Nutr Clin Pract, April 1, 2006; 21(2): 155 - 167. [Abstract] [Full Text] [PDF]

				M. J. Tisdale Clinical Anticachexia Treatments Nutr Clin Pract, April 1, 2006; 21(2): 168 - 174. [Abstract] [Full Text] [PDF]

				D. H. Esper and W. A. Harb The Cancer Cachexia Syndrome: A Review of Metabolic and Clinical Manifestations Nutr Clin Pract, August 1, 2005; 20(4): 369 - 376. [Abstract] [Full Text] [PDF]

				A. Jatoi {Omega}-3 Fatty Acid Supplements for Cancer-Associated Weight Loss Nutr Clin Pract, August 1, 2005; 20(4): 394 - 399. [Abstract] [Full Text] [PDF]

				H. J. Smith, P. Mukerji, and M. J. Tisdale Attenuation of Proteasome-Induced Proteolysis in Skeletal Muscle by {beta}-Hydroxy-{beta}-Methylbutyrate in Cancer-Induced Muscle Loss Cancer Res., January 1, 2005; 65(1): 277 - 283. [Abstract] [Full Text] [PDF]

				H. J. Smith, S. M. Wyke, and M. J. Tisdale Mechanism of the Attenuation of Proteolysis-Inducing Factor Stimulated Protein Degradation in Muscle by {beta}-Hydroxy-{beta}-Methylbutyrate Cancer Res., December 1, 2004; 64(23): 8731 - 8735. [Abstract] [Full Text] [PDF]

				P. Benatti, G. Peluso, R. Nicolai, and M. Calvani Polyunsaturated Fatty Acids: Biochemical, Nutritional and Epigenetic Properties J. Am. Coll. Nutr., August 1, 2004; 23(4): 281 - 302. [Abstract] [Full Text] [PDF]

				A. Jatoi, K. Rowland, C. L. Loprinzi, J. A. Sloan, S. R. Dakhil, N. MacDonald, B. Gagnon, P. J. Novotny, J. A. Mailliard, T. I.L. Bushey, et al. An Eicosapentaenoic Acid Supplement Versus Megestrol Acetate Versus Both for Patients With Cancer-Associated Wasting: A North Central Cancer Treatment Group and National Cancer Institute of Canada Collaborative Effort J. Clin. Oncol., June 15, 2004; 22(12): 2469 - 2476. [Abstract] [Full Text] [PDF]

				C. Belda-Iniesta, J. de Castro Carpeno, J. A. Fresno Vara, P. C. Guerrero, E. C. Saenz, E. E. Arranz, A. R. Sanchez, J. F. Battle, and M. G. Baron Eicosapentaenoic Acid As a Targeted Therapy for Cancer Cachexia J. Clin. Oncol., December 15, 2003; 21(24): 4657 - 4658. [Full Text] [PDF]

				O. A. J. Adegoke, N. Bedard, H. P. Roest, and S. S. Wing Ubiquitin-conjugating enzyme E214k/HR6B is dispensable for increased protein catabolism in muscle of fasted mice Am J Physiol Endocrinol Metab, September 1, 2002; 283(3): E482 - E489. [Abstract] [Full Text] [PDF]

				A. S. Whitehouse, H. J. Smith, J. L. Drake, and M. J. Tisdale Mechanism of Attenuation of Skeletal Muscle Protein Catabolism in Cancer Cachexia by Eicosapentaenoic Acid Cancer Res., May 1, 2001; 61(9): 3604 - 3609. [Abstract] [Full Text]